Mithril Medicine

AI-driven antibody drug discovery platform (agentic drug discovery, closed loop of AI-native protein engineering and high-throughput functional assays).

Develops antibody drugs targeting SIRP. Lead program ipsoprubart (formerly ELA026) is a pan-SIRP monoclonal antibody in the registrational Phase 2/3 SURPASS trial in sHLH and has received FDA Breakthrough Therapy designation; second program ELA822 is a SIRPγ-specific antibody for chronic T cell-mediated immune disorders, with a Phase 1 trial launched in Europe in August 2026

IPO · $302M · 2026-09

AI and robotic automated labs for synthesizing and testing drug molecule variants

$215M · 2026-10 · Valuation $865M

Lab automation: the Keystone™ benchtop all-in-one system combines culturing, intervention and microscopy imaging into uninterrupted multi-day cell/organoid experiments and uses AI vision to identify, count and track cells, generating structured experimental data for AI drug discovery

AI-native drug discovery: proprietary drug foundation models and AI agent engine for early discovery of novel small-molecule, peptide and other drugs

Angel · 2026-09

R&D infrastructure and incubation for early-stage biopharma: shared labs, resident scientists and project management, GMP process optimization, preclinical pharmacology and toxicology, plus an AI drug screening module, for biopharma startups, university and institute spinout teams and multinational pharma

In-house automated wet lab generating large-scale single-cell perturbation data to train "AI virtual cell" models that predict human cell responses to drugs and genetic changes

Seed · 2026-10

Uses AI to simulate biological experiments, accelerating drug discovery and translational research

Series B · $25M · 2026-03

AI-driven drug design platform (IsoDDE engine): uses AlphaFold-based technology to predict protein structures and design new drug molecules; builds its own therapeutic pipeline and conducts joint R&D with large pharmaceutical companies

Series B · $2.7B · 2026-05

AI plus physics-based protein/antibody design platform (GaluxDesign) for drug discovery

Series B · $58M · 2026-02

Develops AI models for drug discovery

AI-driven automated R&D systems for biotech and pharma that simulate experimental outcomes before wet-lab work and recommend the experiments that most reduce uncertainty